Health care costs among renal cancer patients using pazopanib and sunitinib

Journal of Managed Care Pharmacy

Volumn 21, Issue 1, 2015, Pages 37-44

  Hansen, Ryan N ^a   Hackshaw, Michelle D ^b   Nagar, Saurabh P ^b   Arondekar, Bhakti ^b   Deen, Keith C ^b   Sullivan, Sean D ^a,c,d   Ramsey, Scott D ^a,c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB; SUNITINIB; INDOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ARTICLE; CONSULTATION; COST BENEFIT ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADULT; ANOREXIA; ARTHRALGIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DEHYDRATION; DIARRHEA; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HYPERTENSION; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; MALE; MUCOSA INFLAMMATION; PATIENT ASSESSMENT; PLEURA EFFUSION; PROSPECTIVE STUDY; SECONDARY ANALYSIS; TELECONSULTATION; CARCINOMA, RENAL CELL; COMPARATIVE STUDY; ECONOMICS; HEALTH SERVICE; KIDNEY NEOPLASMS; MIDDLE AGED; UNITED STATES; UTILIZATION;

CARCINOMA, RENAL CELL; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES; UNITED STATES;

EID: 84925307909     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.1.37     Document Type: Article

References (23)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29. Available at: http://onlinelibrary.wiley.com/doi/10.3322/ caac.21208/pdf. Accessed November 17, 2014.
2. American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: American Cancer Society. 2010. Available at: http://www.cancer.org/acs/ groups/content/atnho/documents/document/acspc-024113.pdf. Accessed November 17, 2014.
3. Sutent (sunitinib malate) capsules. Pfizer Inc. Revised June 2014. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=607. Accessed November 17, 2014.
4. Votrient (pazopanib) tablets. GlaxoSmithKline. Revised June 2014. Available at: https://www.gsksource.com/gskprm/htdocs/documents/ VOTRIENT-PI-MG.PDF. Accessed November 17, 2014.
5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Kidney cancer, V2. 2014. Available at: http://www.nccn.org/professionals/ physician_gls/pdf/kidney.pdf. Accessed November 17, 2014.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-24. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa065044. Accessed November 17, 2014.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-90. Available at: http://jco.ascopubs.org/content/27/22/3584.full.pdf+html. Accessed November 17, 2014.
8. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-68. Available at: http://jco.ascopubs.org/content/ 28/6/1061.full.pdf+html. Accessed November 17, 2014.
9. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287-96.
10. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-31.
11. Hansen LG, Chang S. Health research data for the real world: the Thomson Reuters MarketScan databases. White Paper. Thomson Reuters. 2011. Available at: http://interest.truvenhealth.com/forms/ HealthResearchWPRequest. Accessed December 8, 2014
12. Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1(1):35-47. Available at: http://biostatistics.oxfordjournals.org/content/ 1/1/35.long. Accessed November 17, 2014.
13. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53(2):419-34. Available at: http:// dlin.web.unc.edu/files/2013/04/LinEA97.pdf. Accessed November 17, 2014.
14. Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. Stat Med. 2005;24(1):131-45.
15. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461-94.
16. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125-44.
17. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. SEER Stat Fact Sheets: kidney and renal pelvis cancer. National Cancer Institute. April 2014. Available at: http://seer.cancer.gov/statfacts/ html/kidrp.html. Accessed November 17, 2014.
18. Weichle T, Hynes DM, Durazo-Arvizu R, Tarlov E, Zhang Q. Impact of alternative approaches to assess outlying and influential observations on health care costs. Springerplus. 2013;2:614. Available at: http://www.ncbi. nlm.nih.gov/pmc/articles/PMC3843184/. Accessed November 17, 2014.
19. Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther. 2013;35(12):1955-63.
20. Hagiwara M, Hackshaw MD, Oster G. Economic burden of selected adverse events in patients aged = 65 years with metastatic renal cell carcinoma. J Med Econ. 2013;16(11):1300-06.
21. Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14(2):1-184, iiiiv. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0014943/ pdf/summ1402.pdf. Accessed November 17, 2014.
22. Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer. 2010;102(1):80-86. Available at: http://www.nature.com/ bjc/journal/v102/n1/pdf/6605417a.pdf. Accessed November 17, 2014.
23. Villa G, Hernández-Pastor LJ. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC Cancer. 2013;13:399. Available at: http://www.biomedcentral.com/content/ pdf/1471-2407-13-399.pdf. Accessed November 17, 2014.